BioSpace: Biotech, Pharmaceutical and Clinical Research News
WEB2024 Q2 Job Market Report: More People Competing for Fewer Job Openings. For the second quarter of 2024, there were 25% fewer jobs posted live on BioSpace compared to the same quarter of 2023. The year-over-year job response rate rose from 14.6% to 15.3%. July 11, 2024. ·.
News - BioSpace
WEBSeptember 12, 2024. ·. 4 min read. ·. Angela Gabriel. Load More. BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. The latest biotech and pharmaceutical news ...
About Us - BioSpace
WEBAbout Us. BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. The proprietary resources we provide help companies make informed decisions regarding their workforce ...
China - BioSpace
WEBWell-financed startup Tome is winding down operations just as two new companies, Borealis Biosciences and GondolaBio, are launching. Meanwhile, in the midst of already tense relations with China, House lawmakers raise the alarm about U.S. companies working with the country’s military on trials. August 28, 2024. ·.
Clinical research - BioSpace
WEBAug 12, 2024 · Pelage Pharmaceuticals Advances Clinical Program with First Patients Dosed in Phase 2 Study for Hair Loss and GV-Led $14M Series A-1. August 13, 2024. 4 min read. Sionna Therapeutics Announces Initiation of Two Phase 1 Clinical Trials of SION-719 and SION-451, in Development for Cystic Fibrosis.
Approvals - BioSpace
WEBFDA. Samsung Bioepis Gets FDA Approval for Biosimilar of J&J’s Stelara. Pyzchiva, developed by Samsung Bioepis, will be commercialized in the U.S. by Sandoz with the license period beginning on Feb. 22, 2025, according to a settlement and licensing agreement with Johnson & Johnson’s Janssen Biotech. July 1, 2024.
FDA News: Approvals, Adcomms, Complete Response Letters and ... - BioSpace
WEBJul 15, 2024 · Approvals. Adcomms. Complete response letters. Guidances. FDA. FDA Tracker: J&J Scores Third NSCLC Approval for Rybrevant This Year. In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA’s decisions in 2024. September 20, 2024.
Asia - BioSpace
WEBHouse Speaker Plans to Vote, Pass BIOSECURE Act into Law This Year. House Speaker Mike Johnson (R-La.) on Monday said he intends to have a “significant package of China-related legislation” signed into law by the end of this year, including the BIOSECURE Act which intends to stop federal contracts with Chinese “companies of concern ...
Cancer - BioSpace
WEBFDA Adcomm Calls for Changes in Perioperative Lung Cancer Trials. The FDA’s Oncologic Drugs Advisory Committee on Thursday strongly supported changing clinical trials for non-small cell lung cancer drugs given in the perioperative setting, pointing out the need for a more nuanced approached to treatments before and after surgery. July 26, 2024.
Biotech, Medical Device & Pharma Startup News | BioSpace
WEBJun 26, 2024 · Weight-Loss Drug Startup Metsera Launches with $290M, Looks to Tap Lucrative Obesity Market. 4/18/2024. The clinical-stage biotech emerged from stealth on Thursday with several oral and injectable candidates, including a GLP-1 receptor agonist in Phase I trials, in an effort to challenge Novo Nordisk and Eli Lilly.